{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:09:18Z","timestamp":1760908158340},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1995]]},"DOI":"10.1007\/bf00686549","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T04:24:52Z","timestamp":1101702292000},"page":"205-212","source":"Crossref","is-referenced-by-count":5,"title":["Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Alexandre","family":"Hageboutros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Rogatko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecelia","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank P.","family":"LaCreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Hudes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Ozols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"61","volume":"1","author":"SG Arbuck","year":"1987","unstructured":"Arbuck SG (1987) 5-FU\/leucovorin. Biochemical modulation that works? Oncology 1:61?71","journal-title":"Oncology"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K","volume":"63","author":"SG Arbuck","year":"1988","unstructured":"Arbuck SG (1988) Overview of clinical trials using 5FU and leucovorin for the treatment of colorectal cancer. Cancer 63: 1036?1044","journal-title":"Cancer"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1200\/JCO.1988.6.6.1053","volume":"6","author":"B Ardalan","year":"1988","unstructured":"Ardalan B, Singh G, Silberman H (1988) Randomized phase I and II study of short-term infusion of high-dose fluorouracil with or withoutN-(phosphonacetyl)-l-aspartic acid in patients with advanced pancreatic and colorectal cancer. J Clin Oncol 6: 1053?1058","journal-title":"J Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/1097-0142(19910915)68:6<1242::AID-CNCR2820680610>3.0.CO;2-5","volume":"68","author":"B Ardalan","year":"1991","unstructured":"Ardalan B, Sridhar KS, Benedette P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A (1991) A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies. Cancer 68: 1242?1246","journal-title":"Cancer"},{"key":"CR5","first-page":"2324","volume":"43","author":"ES Casper","year":"1983","unstructured":"Casper ES, Vale K, Williams LJ, Martin DS, Young CW (1983) Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil withN-(phosphonacetyl)-l-aspartic acid. Cancer Res 43: 2324?2328","journal-title":"Cancer Res"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.1993.11.4.751","volume":"11","author":"LL Danhauser","year":"1993","unstructured":"Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AV (1993) Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11: 751?761","journal-title":"J Clin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1990.8.3.491","volume":"8","author":"JH Doroshow","year":"1990","unstructured":"Doroshow JH, Multhaul P, Leong L, Margolin K, Lichfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, DeLap R, Shuster J, Newman E (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491?501","journal-title":"J Clin Oncol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.1988.6.3.469","volume":"6","author":"C Erlichman","year":"1988","unstructured":"Erlichman C, Fine S, Wong A, Elhadim T (1988) Randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469?475","journal-title":"J Clin Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bjc.1992.335","volume":"66","author":"RA Fleming","year":"1992","unstructured":"Fleming RA, Milano GA, Etienne M-C, Renee N, Thyss A, Schneider M, Demard F (1992) No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day) 5-FU infusion. Br J Cancer 66: 668?672","journal-title":"Br J Cancer"},{"key":"CR10","first-page":"4441","volume":"48","author":"JL Grem","year":"1988","unstructured":"Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B (1988) PALA: biochemistry and clinical activity ofN-phosphonacetyl-l-aspartate: a review. Cancer Res 48: 4441?4454","journal-title":"Cancer Res"},{"key":"CR11","first-page":"3940","volume":"50","author":"JA Houghton","year":"1990","unstructured":"Houghton JA, Williams LG, Cheshire PJ, Wainer IW, Jadaud P, Houghton PJ (1990) Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluoracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 50: 3940?3946","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"CR12","first-page":"3","volume":"14","author":"WM Hryniuk","year":"1987","unstructured":"Hryniuk WM, Figueredo A, Goodyear M (1987) Application of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14 [Suppl 4]: 3?11","journal-title":"Semin Oncol"},{"key":"CR13","first-page":"198","volume":"12","author":"CG Leichman","year":"1993","unstructured":"Leichman CG, Fleming TR, Muggia FM, Ardalan B, Doroshow J, Rangen C, MacDonald J (1993) Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): a Southwest Oncology Group (SWOG) screening trial. Southwest Oncology Group, Seattle, Washington. Proc Am Soc Clin Oncol 12: 198","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR14","first-page":"219","volume":"70","author":"BR Leyland-Jones","year":"1986","unstructured":"Leyland-Jones BR, O'Dwyer PJ (1986) Biochemical modulation: application of laboratory models to the clinic. Cancer Treat Rep 70: 219?229","journal-title":"Cancer Treat Rep"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19800315)45:5+<1117::AID-CNCR2820451316>3.0.CO;2-S","volume":"45","author":"DS Martin","year":"1980","unstructured":"Martin DS, Stolfi RL, Sawyer RC, Nayak R, Spiegelman S, Young CW, Woodcock T (1980) An overview of thymidine. Cancer 45: 1117?1128","journal-title":"Cancer"},{"key":"CR16","first-page":"339","volume-title":"Nucleosides and cancer treatment","author":"DS Martin","year":"1981","unstructured":"Martin DS, Stolfi RL, Sawyer RC, et al (1981) Biochemical modulation of 5-fluorouracil and cytosine arabinoside with emphasis on thymidine, PALA, and 6-methylmercaptopurine riboside. In: Tattersall MHN, Fox RM (eds) Nucleosides and cancer treatment. Academic Press, Sydney, pp 339?382"},{"key":"CR17","first-page":"421","volume":"69","author":"DS Martin","year":"1985","unstructured":"Martin DS, Stolfi RL, Sawyer RC, Young CW (1985) Application of biochemical modulation with therapeutically inactive modulating agents in clinical trials of cancer chemotherapy. Cancer Treat Rep 69: 421?423","journal-title":"Cancer Treat Rep"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/jnci\/80.7.496","volume":"80","author":"DS Martin","year":"1988","unstructured":"Martin DS, Stolfi RL, Colofiore JR (1988) Failure of high-dose leucovorin to improve the therapeutic index of the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance. J Natl Cancer Inst 80: 496?501","journal-title":"J Natl Cancer Inst"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","volume":"10","author":"G Milano","year":"1992","unstructured":"Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171?1175","journal-title":"J Clin Oncol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkeler A (1981) Reporting results of cancer treatment. Cancer 47: 207?214","journal-title":"Cancer"},{"key":"CR21","first-page":"4618","volume":"51","author":"RG Moran","year":"1991","unstructured":"Moran RG, Scanlon KL (1991) Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51: 4618?4623","journal-title":"Cancer Res"},{"key":"CR22","first-page":"5755","volume":"49","author":"EM Newman","year":"1989","unstructured":"Newman EM, Straw JA, Doroshow JH (1989) Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 49: 5755?5760","journal-title":"Cancer Res"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R","volume":"63","author":"MJ O'Connell","year":"1989","unstructured":"O'Connell MJ (1989) A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026?1030","journal-title":"Cancer"},{"key":"CR24","unstructured":"O'Dwyer PJ (1994) Strategies for circumventing clinical resistance to antimetabolites. In: Goldstein LJ, Ozols RF (eds) Drug resistance, (Cancer treatment and research series, vol 3) Kluwer (in press)"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1200\/JCO.1990.8.9.1497","volume":"8","author":"PJ O'Dwyer","year":"1990","unstructured":"O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL (1990) Phase II study of biochemical modulation of 5-fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8: 1497?1503","journal-title":"J Clin Oncol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/jnci\/83.17.1235","volume":"83","author":"PJ O'Dwyer","year":"1991","unstructured":"O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF (1991) Phase I trial of fluorouracil modulation byN-phosphonacetyl-l-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. J Natl Cancer Inst 83:1235?1240","journal-title":"J Natl Cancer Inst"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1200\/JCO.1987.5.10.1559","volume":"5","author":"N Petrelli","year":"1987","unstructured":"Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ, Mittelman A (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559?1565","journal-title":"J Clin Oncol"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1989.7.10.1419","volume":"7","author":"N Petrelli","year":"1989","unstructured":"Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Brucker HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419?1426","journal-title":"J Clin Oncol"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1200\/JCO.1989.7.10.1407","volume":"7","author":"MA Poon","year":"1989","unstructured":"Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullian SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407?1417","journal-title":"J Clin Oncol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.1991.9.11.1967","volume":"9","author":"MA Poon","year":"1991","unstructured":"Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967?1972","journal-title":"J Clin Oncol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00700a012","volume":"13","author":"DV Santi","year":"1974","unstructured":"Santi DV, McHenry CA, Sommer H (1974) Mechanism of interaction of thymidylate snythetase with 5-fluorodeoxyuridylate. Biochemistry 13:471?481","journal-title":"Biochemistry"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1989.59","volume":"59","author":"J Santini","year":"1989","unstructured":"Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring and dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287?290","journal-title":"Br J Cancer"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1073\/pnas.77.8.4966","volume":"77","author":"S Speigelman","year":"1980","unstructured":"Speigelman S, Sawyer R, Nayak R, Ritzi E, Stolfi R, Martin D (1980) Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA 77:4966?4970","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0378-4347(00)82045-9","volume":"344","author":"PL Stetson","year":"1985","unstructured":"Stetson PL, Shukla UA, Ensminger WD (1985) Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma. J Chromatogr 344:385?390","journal-title":"J Chromatogr"},{"key":"CR35","first-page":"190","volume":"23","author":"MB Yin","year":"1983","unstructured":"Yin MB, Zakrzewski SF, Hakala MT (1983) Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 23:190?197","journal-title":"Mol Pharmacol"},{"key":"CR36","first-page":"3476","volume":"51","author":"Z-G Zhang","year":"1991","unstructured":"Zhang Z-G, Rustum YM (1991) Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2?-deoxyuridine and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 51:3476?3481","journal-title":"Cancer Res"},{"key":"CR37","first-page":"10","volume":"19","author":"Z-G Zhang","year":"1992","unstructured":"Zhang Z-G, Harstick A, Rustum YM (1992) Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin Oncol 19:10?15","journal-title":"Semin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686549\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T06:10:58Z","timestamp":1554444658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995]]}},"alternative-id":["BF00686549"],"URL":"https:\/\/doi.org\/10.1007\/bf00686549","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995]]}}}